RxDoctor Payments Data

Carlos Barrero

Family · Baltimore, MDNPI 1215590336

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 25 payments — averaging $42.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$462
  • AbbVie$186
  • Astellas Pharma US Inc$135
  • Viiv Healthcare Company$101
  • Otsuka America Pharmaceutical, Inc.$51
  • Pfizer$49
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,055 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$33,574
Medicare patients
148
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide24$30,412
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,103
OzempicSemaglutide17$20,387
JanuviaSitagliptin Phosphate11$15,118
JardianceEmpagliflozin14$12,009
Flovent HfaFluticasone Propionate11$2,916
Albuterol Sulfate HfaAlbuterol Sulfate100$2,399
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,433
Rosuvastatin Calcium23$941
Atorvastatin Calcium110$883
Ventolin HfaAlbuterol Sulfate15$845
Gabapentin65$677
Amlodipine Besylate93$415
Metoprolol Succinate24$393
Losartan Potassium49$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$14$22,10332 claims
MerckJanuvia$16$15,11811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →